Cite
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
MLA
Thaçi, Diamant, et al. “Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.” Dermatology & Therapy, vol. 12, no. 2, Feb. 2022, pp. 495–510. EBSCOhost, https://doi.org/10.1007/s13555-021-00649-y.
APA
Thaçi, D., Strober, B., Gordon, K. B., Foley, P., Gooderham, M., Morita, A., Papp, K. A., Puig, L., Menter, M. A., Colombo, M. J., Elbez, Y., Kisa, R. M., Ye, J., Napoli, A. A., Wei, L., Banerjee, S., Merola, J. F., & Gottlieb, A. B. (2022). Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology & Therapy, 12(2), 495–510. https://doi.org/10.1007/s13555-021-00649-y
Chicago
Thaçi, Diamant, Bruce Strober, Kenneth B. Gordon, Peter Foley, Melinda Gooderham, Akimichi Morita, Kim A. Papp, et al. 2022. “Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.” Dermatology & Therapy 12 (2): 495–510. doi:10.1007/s13555-021-00649-y.